Testosterone in Women's HRT: the missing hormone

If you've asked a menopause clinic about testosterone and been told "we don't do that for women," you're not alone. The Global Consensus Position Statement on the use of testosterone therapy in women — endorsed by ten international menopause societies — supports low-dose testosterone for postmenopausal women with hypoactive sexual desire disorder (HSDD). Most US clinics still won't prescribe it. Here's the actual science, and why the gap exists.

Women make testosterone too — and lose it earlier than estrogen

Women produce testosterone in the ovaries and adrenal glands, at roughly one-tenth to one-twentieth the level of men. Total testosterone in a healthy premenopausal woman typically runs 15–70 ng/dL, with free testosterone in the 0.3–1.9 pg/mL range depending on the assay.

Here's the part most patients aren't told: testosterone in women peaks in the mid-20s and falls roughly 50% by the mid-40s — well before estrogen drops off in perimenopause. By the time a woman is symptomatic for menopause, her androgen levels have often been low for a decade.

Oophorectomy (surgical removal of the ovaries) drops circulating testosterone by roughly 50% overnight, because the ovaries continue producing androgens even after natural menopause. This is why surgically menopausal women are the most consistently studied group in testosterone trials.

What low-dose testosterone actually does in women

The evidence base isn't small. It's just narrower than the marketing around men's TRT.

Sexual function. The strongest, most replicated finding: transdermal testosterone at doses targeting the upper end of the premenopausal female range improves sexually satisfying events, desire, and arousal in women with HSDD. Davis et al., published in The Lancet Diabetes & Endocrinology (2019), pooled 46 trials and found a clinically meaningful effect on sexual function with an acceptable short-term safety profile.

Mood and wellbeing. Signal is present but softer. Several trials show improvement in energy and mood scores, though the effect is smaller than the sexual function signal and harder to separate from concurrent estrogen therapy.

Lean mass and bone. Physiologic-dose testosterone appears to support lean mass and bone mineral density, particularly when combined with resistance training. This is mechanistically expected — androgen receptors don't care about chromosomes — but the trial data is thinner than the sexual function data.

What it does not reliably do at physiologic doses: cause voice changes, clitoromegaly, or male-pattern hair loss. Those are supraphysiologic-dose problems, and they're the reason dosing matters so much.

The problem isn't that testosterone doesn't work in women. The problem is that the therapeutic window is narrower, and most clinicians aren't trained to dose inside it.

Why most clinics still don't offer it

Three reasons, none of them clinical.

1. No FDA-approved female product in the US. Australia has Androfeme, a licensed 1% testosterone cream for women. The US has nothing. Every prescription written for a woman in the US is either off-label use of a male product (dosed down significantly) or a compounded preparation. Clinics that don't want the regulatory complexity simply opt out.

2. Training gap. Most OB/GYNs finished residency before the 2019 Global Consensus Statement. Testosterone in women wasn't in the curriculum, and there's no incentive to add it now.

3. Ghost of the WHI. The 2002 Women's Health Initiative results made an entire generation of clinicians cautious about any hormone in women. Even though WHI studied oral conjugated estrogens and medroxyprogesterone — not testosterone — the caution generalized.

{callout: The bottom line} Testosterone is a legitimate part of a women's HRT protocol when symptoms and levels support it — but it requires a clinician willing to dose in the female physiologic range and monitor accordingly.

Who is a candidate — and who isn't

The cleanest candidates, based on the international consensus:

• Postmenopausal women (natural or surgical) with HSDD after other causes have been addressed
• Women already on appropriate estrogen therapy who still report low desire, low energy, or reduced sense of wellbeing
• Surgically menopausal women, given the abrupt androgen drop

Candidates who need more caution or aren't appropriate:

• Premenopausal women trying to conceive
• Women with androgen-sensitive conditions (severe acne, hirsutism, PCOS with high baseline androgens)
• Women with a history of hormone-sensitive cancer, pending oncology input
• Anyone expecting testosterone to be a weight-loss drug — it isn't

What a workup looks like — in plain English

Before starting testosterone, the clinical picture that matters is symptoms plus context: a validated desire/function questionnaire, a medication review (SSRIs, oral contraceptives, and opioids all suppress libido or androgens), thyroid status, and a look at estrogen adequacy. Testosterone won't fix a symptom that's actually driven by hypothyroidism or an SSRI.

If you choose to do bloodwork, the markers worth having before a serious protocol are:

• Total testosterone (LC-MS/MS assay preferred — immunoassays are unreliable at female concentrations)
• SHBG — high SHBG binds testosterone and lowers the free fraction
• Free testosterone (calculated or by equilibrium dialysis)
• Estradiol and FSH to stage menopause
• CBC, lipid panel, LFTs as baseline safety markers

Monitoring after starting typically means rechecking total testosterone at 6–8 weeks to confirm you're in the upper physiologic female range — not the male range — and again periodically thereafter.

Dosing without the male-protocol mistake

The single biggest error in female testosterone therapy is treating women like small men. The international consensus is explicit: dosing should target premenopausal physiologic concentrations, which is roughly one-tenth of typical male TRT dosing.

Route matters. Transdermal (cream or gel) has the best evidence base and the most predictable pharmacokinetics in women. Pellets and injections can produce supraphysiologic peaks that drive side effects — the very side effects that give female testosterone therapy a bad reputation. The consensus statement specifically recommends against pellets and injections for this reason.

Specific titration ranges belong in a clinician conversation, not a blog post, but the principle is: start low, recheck labs, adjust based on symptom response and level — not on how the number would look on a male chart.

Realistic expectations

If testosterone is going to help, most women notice something in 8–12 weeks. Desire and arousal tend to shift first. Energy and mood are more variable. Body composition changes require the therapy plus consistent resistance training — testosterone doesn't build muscle from the couch, in any sex.

If nothing has changed at 6 months on a well-dosed protocol with levels confirmed in range, testosterone probably isn't the answer for that patient, and continuing it isn't warranted.

The honest summary

Testosterone is not a fringe hormone for women. It's a physiologic hormone that declines with age, has a defined role in sexual function and wellbeing, and has an international consensus supporting its use in a specific population. The barrier to access in the US is regulatory and educational — not scientific.

A women's HRT protocol that automatically excludes testosterone isn't being cautious. It's being incomplete. The right question isn't whether testosterone belongs in the conversation — it's whether your symptoms, levels, and goals put you in the group the evidence actually supports.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.